SELLAS Life Sciences Group, Inc. (SLS) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
the bull case· 3
9
disclosed supplier and customer ties in SEC filings
sec filingsedgar1 of 21
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26+35.86%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
6 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized17
managers whose positions together make up four fifths of the reported value
13fJun 30 '261.19%
of State Street SPDR S&P Biotech ETF's assets the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
SLS (SELLAS Life Sciences Group, Inc.) has 9 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Of the 6 companies SELLAS Life Sciences Group, Inc. moves with most closely, none share its SEC classification.
Measured against 305 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
SELLAS Life Sciences Group, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 11.58 at 4:45 pm ET, low 11.12 at 2:15 pm ET.
tall tick = annual report · 1 on record
208 managers report a position worth $1.5B between them, and 17 of them hold 80% of it.